Novel perspective: Exercise training stimulus triggers the expression of the oncoprotein human double minute-2 in human skeletal muscle

Physiological Reports

Volumn 1, Issue 2, 2013, Pages

  Roudier, Emilie ^a   Aiken, Julian ^a   Slopack, Dara ^a   Gouzi, Fares ^b   Mercier, Jacques ^b   Haas, Tara L ^a   Gustafsson, Thomas ^c   Hayot, Maurice ^b   Birot, Olivier ^a  

^a York University   (Canada)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

FoxO1; Mdm2; PECAM 1

Indexed keywords

CARBON DIOXIDE; CD31 ANTIGEN; PROTEIN MDM2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD PRESSURE; ELECTROCARDIOGRAPHY; EXERCISE; EXHAUSTION; FEMALE; HEART RATE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MUSCLE BIOPSY; MUSCLE BLOOD VESSEL; OXYGEN CONSUMPTION; OXYGEN SATURATION; PROTEIN EXPRESSION; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE; WESTERN BLOTTING;

EID: 85008937076     PISSN: None     EISSN: 2051817X     Source Type: Journal    
DOI: 10.1002/phy2.28     Document Type: Article

References (31)

1. Arden, K. C. 2007. FoxOs in tumor suppression and stem cell maintenance. Cell 128: 235–237.
2. Ballard-Barbash, R., C. M. Friedenreich, K. S. Courneya, S. M. Siddiqi, A. McTiernan, and C. M. Alfano. 2012. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J. Natl. Cancer Inst. 104: 815–840.
3. Busuttil, V., N. Droin, L. McCormick, F. Bernassola, E. Candi, G. Melino, et al. 2010. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of Mdm2. Proc. Natl. Acad. Sci. USA 107: 18061–18066.
4. Carroll, V. A., and M. Ashcroft. 2008. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res. 68: 545–552.
5. Chen, J., V. Marechal, and A. J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13: 4107–4114.
6. Dameron, K. M., O. V. Volpert, M. A. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265: 1582–1584.
7. Egginton, S. 2009. Invited review: activity-induced angiogenesis. Pflugers Arch. 457: 963–977.
8. Fu, W., Q. Ma, L. Chen, P. Li, M. Zhang, S. Ramamoorthy, et al. 2009. MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation. J. Biol. Chem. 284: 13987–14000.
9. Gouzi, F., C. Prefaut, A. Abdellaoui, E. Roudier, P. de Rigal, N. Molinari, et al. 2013. Blunted muscle angiogenic training-response in COPD patients versus sedentary controls. Eur. Respir. J. 41: 806–814.
10. Hayot, M., A. Michaud, C. Koechlin, M. A. Caron, P. Leblanc, C. Prefaut, et al. 2005. Skeletal muscle microbiopsy: a validation study of a minimally invasive technique. Eur. Respir. J. 25: 431–440.
11. Keller, P., N. B. J. Vollaard, T. Gustafsson, I. J. Gallagher, C. J. Sunberg, T. Rankinen, et al. 2011. A transcriptional map of the impact of endurance exercise training on skeletal muscle phenotype. J. Appl. Physiol. 110: 46–59.
12. Lee, N. V., M. Sato, D. S. Annis, J. A. Loo, L. Wu, D. F. Mosher, et al. 2006. ADAMTS1 mediates the release of anti-angiogenic polypeptides from TSP-1 and 2. EMBO J. 25: 5270–5283.
13. Li, Q., and G. Lozano. 2013. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy. Clin. Cancer Res. 19: 34–41.
14. Marine, J. C., and G. Lozano. 2010. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ. 17: 93–102.
15. Mendysa, S. M., K. A. O’Leary, M. K. McElwee, J. Michalowski, R. N. Eisenman, D. A. Powell, et al. 2006. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20: 16–21.
16. Milkiewicz, M., E. Roudier, J. L. Doyle, A. Trifonova, O. Birot, and T. L. Haas. 2011. Identification of a mechanism underlying regulation of the anti-angiogenic forkhead transcription factor FoxO1 in cultured endothelial cells and ischemic muscle. Am. J. Pathol. 178: 935–944.
17. Millard, M., D. Pathania, F. Grande, S. Xu, and N. Neamati. 2011. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Curr. Pharm. Des. 17: 536–559.
18. Mishra, S. I., R. W. Scherer, C. Snyder, P. M. Geigle, D. R. Berlanstein, and O. Topaloglu. 2012. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst. Rev. 8: CD008465. doi: 10.1002/14651858.CD008465.pub2.
19. Nici, L., C. Donner, E. Wouters, R. Zuwallack, N. Ambrosino, J. Bourbeau, et al. 2006. American thoracic society/European respiratory society statement on pulmonary rehabilitation. Am. J. Respir. Crit. Care Med. 173: 1390–1413.
20. Nieminen, A. L., S. Qanungo, E. A. Schneider, B. H. Jiang, and F. H. Agani. 2005. Mdm2 and HIF-1 alpha interaction in tumor cells during hypoxia. J. Cell. Physiol. 204: 364–369.
21. Olfert, I. M., and O. Birot. 2011. Importance of anti-angiogenic factors in the regulation of skeletal muscle angiogenesis. Microcirculation 18: 316–330.
22. Ross, R. M. 2003. ATS/ACCP statement on cardiopulmonary exercise testing. Am. J. Respir. Crit. Care Med. 167: 211–277.
23. Roudier, E., N. Chapados, S. Decary, C. Gineste, C. Le Bel, J. M. Lavoie, et al. 2009. Angiomotin p80/p130 ratio: a new indicator of exercise-induced angiogenic activity in skeletal muscles from obese and non-obese rats? J. Physiol. 587: 4105–4119.
24. Roudier, E., P. Forn, M. E. Perry, and O. Birot. 2012. Murine Double Minute-2 expression is required for capillary maintenance and exercise-induced angiogenesis in skeletal muscle. Faseb J. 26: 4530–4539.
25. Roudier, E., M. Milkiewicz, O. Birot, D. Slopack, A. Montelius, T. Gustafsson, et al. In press. Endothelial Foxo1 is an intrinsic regulator of thrombospondin 1 expression that restrains angiogenesis in ischemic muscle. Angiogenesis. doi: 10.1007/s10456-013-9353-x.
26. Secchiero, P., R. Bosco, C. Celeghini, and G. Zauli. 2011. Recent advances in the therapeutic perspectives of Nutlin-3. Curr. Pharm. Des. 17: 569–577.
27. Soussi, T., and K. G. Wiman. 2007. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12: 303–312.
28. Thomasova, D., S. R. Mulay, H. Bruns, and H.-J. Anders. 2012. P53-independent roles of Mdm2 in NF-kB signaling: implications for cancer therapy, wound healing, and autoimmune diseases. Neoplasia 14: 1097–1101.
29. Toledo, F., and G. M. Wahl. 2006. Regulating the p53 pathway: in vitro hypothesis, in vivo veritas. Nat. Rev. Cancer 6: 909–923.
30. Vassilev, L. T. 2007. MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13: 23–31.
31. Wagner, P. D. 2010. The physiological basis of reduced VO2max in Operation Everest II. High Alt. Med. Biol. 11: 209–215.